INDIANAPOLIS, June 5, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present data for Taltz ® (ixekizumab), Olumiant ® (baricitinib) and mirikizumab at the 24th World Congress of ...
TORONTO, June 05, 2020 (GLOBE NEWSWIRE) -- TALTZ ® (ixekizumab) demonstrated consistent efficacy and long-term potential to help patients with psoriatic arthritis (PsA) in new data presented virtually ...
Short-term improvements in axial spondyloarthritis (axSpA) symptoms seen with the interleukin-17A blocker ixekizumab (Taltz) persisted and even increased further among clinical trial participants who ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback